14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.03 $5.16 Thursday, 2nd May 2024 BCRX stock ended at $4.48. This is 1.97% less than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 6.12% from a day low at $4.41 to a day high of $4.68.
90 days $4.03 $6.35
52 weeks $4.03 $8.96

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
Mar 29, 2023 $8.62 $8.69 $8.37 $8.56 2 567 972
Mar 28, 2023 $8.43 $8.65 $8.35 $8.59 2 047 206
Mar 27, 2023 $8.48 $8.57 $8.37 $8.46 1 449 361
Mar 24, 2023 $8.11 $8.57 $8.08 $8.50 2 697 700
Mar 23, 2023 $7.99 $8.32 $7.95 $8.12 2 018 253
Mar 22, 2023 $8.16 $8.24 $7.92 $7.94 1 951 420
Mar 21, 2023 $8.05 $8.24 $7.95 $8.17 1 985 852
Mar 20, 2023 $8.13 $8.13 $7.95 $8.01 2 025 911
Mar 17, 2023 $8.08 $8.18 $8.01 $8.10 5 228 495
Mar 16, 2023 $8.35 $8.43 $8.16 $8.17 1 858 384
Mar 15, 2023 $8.20 $8.61 $8.15 $8.37 2 986 092
Mar 14, 2023 $8.50 $8.60 $8.25 $8.32 3 416 738
Mar 13, 2023 $8.29 $8.54 $8.19 $8.31 6 039 363
Mar 10, 2023 $8.18 $8.31 $7.82 $8.29 4 512 208
Mar 09, 2023 $8.58 $8.62 $8.10 $8.21 3 793 176
Mar 08, 2023 $8.65 $8.70 $8.40 $8.56 2 293 861
Mar 07, 2023 $8.88 $8.90 $8.65 $8.65 1 589 984
Mar 06, 2023 $8.79 $8.90 $8.67 $8.84 3 742 398
Mar 03, 2023 $8.93 $8.95 $8.74 $8.79 2 559 009
Mar 02, 2023 $8.75 $8.91 $8.62 $8.86 2 653 138
Mar 01, 2023 $8.99 $8.99 $8.64 $8.83 3 442 518
Feb 28, 2023 $9.00 $9.14 $8.78 $8.85 5 653 935
Feb 27, 2023 $9.20 $9.20 $8.98 $9.03 3 431 753
Feb 24, 2023 $9.33 $9.33 $9.06 $9.10 2 219 102
Feb 23, 2023 $9.65 $9.73 $9.25 $9.44 2 889 826
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT